As a pioneer in the drug transporter field for 20 years, SOLVO is dedicated to exploring the science of transporters and their role in xenobiotic efficacy and safety. With frequent Webinars hosted by respected scholars and professionals, as well as numerous peer-reviewed publications, our commitment and scientific contribution to the transporter field is well recognized.
After the great success of our events in SOLVO’s Meet the Experts: Transporter Conference series, we are pleased to announce that the tenth event will be held in Seoul on 14 November, 2019. With the Meet the Experts: Transporter Conference series, we took our commitment to the transporter field to a new level. The sessions will focusing on the most relevant and up-to-date aspects of transporter science and industry applications.
Venue: The conference will be organized at JW Marriott Hotel Seoul. One of the city's most distinguished destinations, JW Marriott Hotel Seoul welcomes travelers to the Gangnam District in five-star style. Address: 176, Sinbanpo-ro, Seocho-gu, Seoul 06546 South Korea
Early Bird Registration Fee until 31 August 2019: $50
Standard Registration Fee from 31 August 2019: $75
Payment can be made by wire-transfer or credit card. Please click here for credit card authorization form.
Cancellation policy: “Refunds will be issued for all requests received by the 20 August 2019. Refunds will not be issued for requests received after 20 August 2019.” Send cancellation request to firstname.lastname@example.org.
Your registration fee covers besides the conference program, lunchbox, coffee breaks, reception.
|Chair: Joe Zolnerciks and Roelof de Wilde, SOLVO Biotechnology|
|09:15-||30||Registration and Coffee with snacks|
|09:45-||15||Opening||Péter Krajcsi, PhD, SOLVO Biotechnology|
|Durg Discovery and Development|
|10:00-||40||Keynote: The Next Frontier in ADME Science: Predicting and Verifying Tissue Drug Exposure||Jashvant Unadkat, PhD, University of Washington|
|10:40-||30||Contribution of Xenobiotic Transporters to Drug Disposition||Jasminder Sahi, PhD,Sanofi-Aventis (China)|
|11:10-||30||In Vitro Platforms for De-risking Nephrotoxicity||Colin Brown, PhD, Newcastle University|
|11:40-||60||Lunch Seminar: Solutions by SOLVO to support your ADME-Tox research: Beáta Kovács, M, PhD, SOLVO Biotechnology|
|Barriers and Transporters|
|12:40-||40||Keynote: Regulation Mechanism of P-gp in the Blood-Brain Barrier||Tetsuya Terasaki, PhD, Tohoku University|
|13:20-||30||Long-lasting Inhibition of OATPs: Update on the Mechanisms and Impact||Wooin Lee, PhD, Seoul National University|
|13:50-||30||OATP2A1/SLCO2A1 Determines Prostaglandins’ Action by Distributing Them to the Required Place at the Right Time||Takeo Nakanishi, PhD, Takasaki University|
|Transport and Metabolism|
|14:50-||40||Keynote: Food Effect on Intestinal Transporters ASBT and OATP2B1||Ikumi Tamai, PhD, Kanazawa University|
|15:30-||30||Integrated In Vitro and In Vivo Approaches to Drug Metabolism Investigations - a Study Case||Massimiliano Fonsi, PhD, Citoxlab, a Charles River Company|
|16:00-||30||Nasal Route for CNS Drug Repurposing and Novel Delivery to the Brain||Joan Z Zuo, PhD, Chinese University of Hong Kong|
|16:30-||20||Closing Remarks||Péter Krajcsi, SOLVO|
*We reserve the right to change the Agenda.
Associate Professor Institute for Cell & Molecular Biosciences, Medical School, Newcastle University Newcastle, UK
Dr Colin Brown was awarded a B.Sc and Ph.D in Physiology and Pharmacology from the University of St Andrews Scotland. He then was a Royal Society European Postdoctoral Research Fellow at the University of Zurich, Switzerland, followed by a Wellcome Trust Senior Fellowship in Biomedical Sciences at the University of Manchester. Until recently, Colin was an Associate Professor at the University of Newcastle where he focussed on developing in vitro models to study drug transport, drug interactions and toxicity in kidney, developing the aProximate in vitro PTC model. In 2018, Dr Brown joined Newcells Biotech as Director of ADMET Technologies.
DMPK Director, Citoxlab, a Charles River Company, France
Dr. Fonsi is currently responsible of the DMPK department at Citoxlab, a Charles River company, with a role that is both managerial and scientific. He has more than twenty years’ experiences in drug discovery and development and particularly in the field of drug metabolism and metabolism mediated toxicity and DDI. Before joining Citoxlab, he worked at Merck MSD, UCB, Addex, where he has actively participated in the discovery of Zolinza, Isentress, Niraparib, Grazoprevir and other candidate drugs currently in clinical phase. His area of competence covers both discovery and regulatory ADME, including toxicokinetics. Dr. Fonsi is actively involved, in collaboration with academia and biotech companies, in developing new in vitro ADMET models (essentially for hepatotoxicity and thyroid toxicity via (secondary) hepatic enzyme modulation) for the determination of likelihood of human adverse outcomes using complementary in vitro and in silico models for interspecies extrapolation. Dr. Fonsi has been member of the scientific committee of the French “Groupe de Métabolisme et Pharmacocinétique” (GMP) congress in the recent past. Starting from 2019 he is also member of the steering board of the GMP organization.
Associate Professor, College of Pharmacy, Seoul National University, Seoul, Korea
Wooin Lee obtained her PhD degree at the Department of Pharmaceutical Sciences, College of Pharmacy, University at Buffalo, SUNY in the USA. She did her postdoctoral training at the Division of Clinical Pharmacology at Vanderbilt University. After that, she joined the research faculty working closely with clinical oncologists and the early drug development team at the Vanderbilt-Ingram Cancer Center. She was an Assistant and Associate Professor at the Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky. In 2014, she moved back to South Korea and is currently an Associate Professor at the College of Pharmacy, Seoul National University. Her research interest lies in understanding the genetic, epigenetic and molecular bases for variable drug response and drug interactions with a focus on membrane transporters and developing novel anticancer drugs targeting the proteasomes and their delivery strategies to achieve desirable pharmacokinetic and pharmacodynamic profiles. She has also been pursuing research in pharmacokinetic modeling and simulation using preclinical and clinical data. She has authored over 80 peer-reviewed publications.
Professor, Takasaki University of Health and Welfare Faculty of Pharmacy, Japan
Dr. Takeo Nakanishi has more than 20 years of experience in biopharmaceutics. He received his Ph.D. in pharmaceutical sciences from Kanazawa University, and later had post-doc terms in Medical College of Georgia, Augusta, GA and Greenebaum Cancer Center, the University of Maryland at Baltimore, MD, USA. He currently appointed to a professor in Faculty of Pharmacy, Takasaki University of Health and Welfare. In his academic career, he has focused on 1) MDR transporters, in particular, ABCG2, in cancer cells, and 2) molecular biology of physiologically important transporters. For the past decade, he has been working in Kanazawa University to understand the pathophysiological significance of solute carriers for amino acids, urate, steroid hormones, and prostaglandins. Research on unappreciated roles of these carriers may hold much promise for new approaches in developing effective therapies for refractory diseases related to cancer and chronic inflammation.
Senior Director, Department of Translational Medicine and Exploratory Development, Sanofi R&D, China
Jasminder Sahi obtained a Ph.D. degree (Pharmacognosy, 1991) from Panjab University, India and then participated in a post-doctoral program in the Department of Physiology and Biophysics, University of Illinois at Chicago. She started her career in the Pharmaceutical Industry in the Department of Pharmacokinetics and Drug Metabolism (Parke Davis R&D), which was subsequently acquired by Pfizer Global Research and Development. In 2006, she joined a new venture (CellzDirect) as the Vice President R&D. In 2012 she moved to Shanghai China, as Head of DMPK for GlaxoSmithKline Research and Development and in 2015 made the transition to Sanofi R&D leading the DMPK efforts in the Asia Pacific region. Jasminder’s research focus is on transporters and induction of drug metabolizing enzymes, using primary hepatocytes. While her initial forays into transporter research involved ion transport to understand CFTR, at Pfizer she changed her focus to xenobiotic transporters, with the goal of improving drug disposition, delivery and safety. She has worked extensively with hepatic and renal transporters as well as the blood-brain-barrier. She is an elected member of the ISSX council, a reviewer for six journals and has authored over 40 peer-reviewed publications.
Professor Institute of Medical, Pharmaceutical and Health Sciences, Faculty of Pharmaceutical Sciences, Kanazawa University Kanazawa, Japan
Education and Professional Experiences;
BS, Kanazawa University 1982, Ph.D; University of Tokyo 1988; Post-doctoral Fellow, University of Chicago and University of Michigan (1989-1991); Professor, Tokyo University of Science (2002-2008); Kanazawa University, Institute of Medical, Pharmaceutical and Health Sciences 2008-present. Head, Venture Business Laboratory, Kanazawa University (2014 – present).
Japanese Society for the Study of Xenobiotics (JSSX); Academy of Pharmaceutical Science and Technology, Japan (APSTJ); Pharmaceutical Society of Japan (PSJ); Japanese Society of Gout and Nucleic Acid Metabolism; American Association of Pharmaceutical Scientists (AAPS); American Society for Pharmacology and Experimental Therapeutics (ASPET); International Society for the Study of Xenobiotics (ISSX).
Board of Committee:
Committee Member of Food Safety Commission, Cabinet Office, Government of Japan (2006 - present); Associate Editor, Biopharmaceutics and Drug Disposition (2009 - present); Editor, Pharmaceutical Research (2017 - present); Councilor, JSSX (2006 – 2013, 2017 - present); Councilor, ISSX (2010 - 2013); Editor in Chief, Drug Metabolism and Pharmacokinetics (DMPK) (2010 - 2013); Associate Editor, Biological Pharmaceutical Bulletin. (2006 - 2008); Editorial Board Member for Journal of Pharmaceutical Sciences, Molecular Pharmaceutics, Pharmaceutical Research and Drug Metabolism and Disposition.
Research of Interest:
Transporters related to Drug-Drug Interaction, Drug-Food Interaction, Drug-induced Toxicity, Regulation of Uric Acid and Prostaglandins, Drug Absorption and Pharmacokinetics.
Distinguished Professor Membrane Transport and Drug Targeting Laboratory, Graduate School of Pharmaceutical Sciences, Tohoku University Sendai, Japan
Dr. Tetsuya Terasaki graduated Kanazawa University in 1977 and received Ph.D. degree from University of Tokyo in 1982. He was appointed Full Professor of Tohoku University in 1996 and the University Distinguished Professor of Tohoku University in 2008. He received the Ebert Prize from American Pharmaceutical Association in 1985, the Meritorious Manuscript Award from American Association of Pharmaceutical Scientists in 1996 and 2010, together with three Research Achievement Awards. In April 2013, he received the Medal of Honor with Purple Ribbon, bestowed by the Government of Japan to the most highly honored scientists. His major research interests are the molecular pharmacology of blood-brain barrier function and the pharmacoproteomics. He published extensively in journals, with 309 original research articles and 70 review articles and contributed chapters to over 50 books.
Professor of Pharmaceutics in the School of Pharmacy, University of Washington, Seattle, US
Jashvant (Jash) Unadkat, Ph.D. is the Milo Gibaldi Endowed Professor at the School of Pharmacy, University of Washington, Seattle. He received his Bachelor degree in Pharmacy (B.Pharm.) from the University of London (1977), his Ph.D. from the University of Manchester (1982) and his postdoctoral training at the University of California at San Francisco (1982-85). Dr. Unadkat studies the mechanisms of transport and metabolism of drugs, including during pregnancy. Dr. Unadkat has published more than 200 peer-reviewed research papers. He is a fellow of AAAS, AAPS, JSSX, and the founding co-chair (1999-2001) of the focus group of AAPS on Drug Transport and Uptake. Dr. Unadkat received the AAPS Research Achievement Award in 2012. Dr. Unadkat created and leads the UW Research Affiliates Program on Transporters (UWRAPT), funded by pharmaceutical companies and UWPKDAP, a NIDA funded Program Project grant (P01) on drug disposition during pregnancy.